You are here

Home » Content

Skuamöz Hücreli Baş Boyun Kanserinde Kemoradyoterapi

Chemoradiotherapy in the Head and Neck Squamous Cell Cancer

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
The treatment of head and neck squmaous cell cancer (HNSSC) requires a multidisciplinary management. Postoperative chemoradiotherapy (CRT) has been the gold standart in the patients with early stage HNSSC with poor prognostic factors. The treatment of locally advanced HNSSC includes surgery and adjuvant CRT, induction chemotherapy followed by definitive CRT or CRT alone. Induction chemotherapy followed by definitive CRT has been a successful approach for organ preservation, in particularly operable HNSSC. It has been demonstrated that the greatest survival benefit over radiotherapy (RT) alone is seen with the CRT in several trials. Specifically, to improve the efficacy of the treatment for organ preservation, it has been explored new induction combination regimens with taxanes and found to be more efficient comparing with the cisplatin-5 fluorouracil regimens. The favorable efficiency of the concomitantly usage of taxans with RT, has been demonstrated in only Phase II studies. More recently, the improving efficacy of epidermal growth factor receptor inhibitor (Cetuximab) combined with RT has been determined on survival in several trials. In this review, we overviewed the current literatures within the future role of new agents on the base of clinical trials.
Bookmark/Search this post with
Abstract (Original Language): 
Skuamöz hücreli baş boyun kanserinin (SHBBK) tedavisi multisipliner yaklaşımı gerektirmektedir. Erken evre SHBBK’de postoperatif yüksek risk faktörü olan olgularda adjuvan KRT altın standarttır. Lokal ileri evre SHBBK’de ise tedavi; cerrahi ve adjuvan kemoradyoterapi (KRT), indüksiyon kemoterapi (KT) sonrası definitif KRT ya da sadece KRT’yi içermektedir. Özellikle operabıl SHBBK’de indüksiyon kemoterapi sonrası KRT, organ koruma için başarılı bir tedavi yaklaşımıdır. Birçok çalışmada KRT sadece radyoterapiye (RT) göre belirgin sağkalım avantajıyla beraber olduğu gösterilmiştir. Özellikle organ koruyucu tedavide, tedavi etkinliğini artırmak için taksanlarla beraber yeni indüksiyon KT kombinasyonları araştırılmış ve sonuçlar sisplatin-5-flourasil tedavisine göre daha etkili bulunmuştur. RT ile eş zamanlı taksan kullanımının etkinliği ise sadece Faz II çalışmalarda gösterilmiştir. Son dönemde yapılan çalışmalarda, epidermal büyüme faktör reseptör inhibitörü (Setuksimab) ile RT kombinasyonunun sağkalım üzerinde olumlu etkinliği saptanmıştır. Bu derlemede, klinik çalışmalar zemininde güncel literatürleri inceleyerek, yeni ajanların gelecekteki rolünü gözden geçirdik.
FULL TEXT (PDF): 
PDF icon arastirmax-skuamoz-hucreli-bas-boyun-kanserinde-kemoradyoterapi.pdf
  • 1
61-65
  • Turkish

REFERENCES

References: 

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA
Cancer J Clin 2010; 60 : 277-300
2. Cooper JS, Porter K, Mallin K, et al. National Cancer Database
report on cancer of the head and neck: 10-year update. Head
Neck 2009 ; 31 : 748-58.
3. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck
cancer. N Engl J Med 2001; 345 : 1890-900.
4. Posner MR, Haddad RI, Wirth L, et al. Induction chemotherapy
in locally advanced squamous cell cancer of the head and neck:
evolution of the sequential treatment approach. Semin Oncol
2004 ; 31 : 778-85
5. Agrawal N, Ha PK. Management of early-stage laryngeal
cancer. Otolaryngol Clin North Am 2008 ; 41 : 757-69.
6. Scher RL, Esclamado RM. Organ and function preservation:
the role of surgery as the optimal primary modality or as salvage after chemoradiation failure. Semin Radiat Oncol 2009 ;
19 : 17-23.
7. Pignon JP, le Maître A, Bourhis J; MACH-NC Collaborative
Group. Meta-Analyses of Chemotherapy in Head and Neck
Cancer (MACH-NC): an update. Int J Radiat Oncol Biol
Phys 2007 ; 69: 112-4.
8. Garden AS, Asper JA, Morrison WH, et al. Is concurrent
chemoradiation the treatment of choice for all patients with
Stage III or IV head and neck carcinoma? Cancer 2004 ; 100 :
1171-8.
9. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated
irradiation with or without concurrent chemotherapy for locally
advanced head and neck cancer.N Engl J Med 1998; 338 :
1798-804.
10. Cruz JJ, Ocaña A, Navarro M, Barco ED, Fonseca E. New
options in the treatment of locally advanced head and neck cancer: role for induction chemotherapy. Cancer Treat Rev 2008
;34 : 268-74.
11. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for
locally advanced, nonmetastatic, squamous carcinoma of the
head and neck: consensus, controversy, and conundrum. J Clin
Oncol 2006 ; 24 : 2612-7.
12. Glynne-Jones R, Sebag-Montefiore D. Chemoradiation schedules--what radiotherapy? Eur J Cancer 2002 ; 38 : 258-69.
13. Bernier J, Cooper JS, Pajak TF,et al. Defining risk levels in
locally advanced head and neck cancers: a comparative analysis
of concurrent postoperative radiation plus chemotherapy trials
of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005
; 27 : 843-50.
14. Corvò R. Evidence-based radiation oncology in head and neck
squamous cell carcinoma. Radiother Oncol 2007 ; 85 : 156-70.
15. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III
comparison of standard radiation therapy and two schedules of
concurrent chemoradiotherapy in patients with unresetable
squamous cell head and neck cancer. J Clin Oncol 2003;21 :
92-8.
16. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003 ; 349 : 2091-8.
17. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette
L, Sahmoud T. Larynx preservation in pyriform sinus cancer:
preliminary results of a European Organization for Research
and Treatment of Cancer phase III trial. EORTC Head and
Neck Cancer Cooperative Group. J Natl Cancer Inst 1996 ; 88 :
890-9.
18. Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in
resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003; 21 : 327-33.
19. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and
fluorouracil alone or with docetaxel in head and neck cancer. N
Engl J Med 2007 ; 357 : 1705-15.
20. Allal AS, Nicoucar K, Mach N, Dulguerov P. Quality of life in
patients with oropharynx carcinomas: assessment after accelerated radiotherapy with or without chemotherapy versus radical
surgery and postoperative radiotherapy. Head Neck 2003 ; 25
:833-9.
21. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and
neck cancer. Lancet 2008 ; 371 : 1695-709.
22. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized
trial on larynx preservation comparing sequential vs alternating
chemotherapy and radiotherapy. J Natl Cancer Inst. 2009 ; 101 :
142-52.
23. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of
induction chemotherapy with cisplatin and 5-fluorouracil with
or without docetaxel for larynx preservation. Natl Cancer
Inst 2009 ; 101 : 498-506.
24. Posner MR, Norris CM, et al. Sequential therapy for the locally
advanced larynx and hypopharynx cancer subgroup in TAX
324: survival, surgery, and organ preservation. Ann Oncol 2009
; 20 : 921-7.
25. Worden FP, Moyer J, Lee JS, Taylor JM, et al. Chemoselection
as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
Laryngoscope 2009 ; 119 : 1510-7.
26. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy
versus radiotherapy in patients with advanced nasopharyngeal
cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16 : 1310-7.
27. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin
significantly improves locoregional control in advanced head
and neck cancers treated with hyperfractionated radiotherapy. J
Clin Oncol 2004 ;22 : 4665-73.
28. Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine
MN. Placebo-controlled randomized trial of infusional
fluorouracil during standard radiotherapy in locally advanced
head and neck cancer. J Clin Oncol 1994; 12 : 2648-53.
29. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin,
fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007 ; 357 : 1695-704.
30. Rewari AN, Haffty BG, Wilson LD, et al. Postoperative concurrent chemoradiotherapy with mitomycin in advanced
squamous cell carcinoma of the head and neck: results from
three prospective randomized trials. Cancer J 2006 ; 12 : 123-
9.
31. Gupta NK, Pointon RC, Wilkinson PM. A randomised clinical
trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin
Radiol 1987 ; 38 : 575-81.
32. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus
cetuximab for squamous-cell carcinoma of the head and neck.
N Engl J Med 2006 ; 354 : 567-78.
33. Budach W, Hehr T, Budach V, Belka C, Dietz K. A metaanalysis of hyperfractionated and accelerated radiotherapy and
combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head
and neck. BMC Cancer 2006 ; 6 : 28.
34. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy
added to locoregional treatment for head and neck squamouscell carcinoma: three meta-analyses of updated individual data.
MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000 ; 355 : 949-55.
35. Pignon JP, le Maître A, Maillard E. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93
randomised trials and 17,346 patients. Radiother Oncology
2009; 92 : 4-14. Baş Boyun Kanserinde Kemoradyoterapi
65
36. Forastiere, M. Maor, R. S. Weber, et al. Long-term results of
Intergroup RTOG 91-11: A phase III trial to preserve the larynx--Induction cisplatin/5-FU and radiation therapy versus
concurrent cisplatin and radiation therapy versus radiation therapy. Journal of Clinical Oncology 2006 (5517) ; 24: 18S.
37. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01
French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant
radiochemotherapy in advanced-stage oropharynx carcinoma. J
Clin Oncol 2004 ; 22 : 69-76.
38. Semrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified
hyperfractionated and accelerated radiotherapy and concurrent
chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-andneck cancer. Int J Radiat Oncol Biol Phys 2006 ; 64 : 1308-16.
39. Forastiere AA, Natale RB, Takasugi BJ, Goren MP, Vogel WC,
Kudla-Hatch V. A phase I-II trial of carboplatin and 5-
fluorouracil combination chemotherapy in advanced carcinoma
of the head and neck. J Clin Oncol 1987 ; 5 : 190-6.
40. Calais G, Alfonsi M, Bardet E, Bull Cancer. Stage III and IV
cancers of the oropharynx: results of a randomized study of
Gortec comparing radiotherapy alone with concomitant chemotherapy. 2000 ; 87 : 48-53.
41. Brizel DM, Vokes EE. Induction chemotherapy: to use or not to
use? That is the question. Semin Radiat Oncol. 2009 ; 19 : 11-6
42. Posner M, Vermorken JB. Induction therapy in the modern era
of combined-modality therapy for locally advanced head and
neck cancer. Semin Oncol 2008 ; 35 : 221-8.
43. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of
failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004 ; 15 : 1179-86.
44. Vokes EE, Mick R, Kies MS, et al. Pharmacodynamics of
fluorouracil-based induction chemotherapy in advanced head
and neck cancer. J Clin Oncol 1996 ; 14 : 1663-71.
45. Devlin PM, Kazakin J, Adak S, et al. Prospective phase II trial
of PFL-induction chemotherapy followed by definitive local
treatment for advanced squamous cell carcinoma of the head
and neck: 10-year follow-up. Am J Clin Oncol 2004; 27 : 369-
75.
46. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of
neoadjuvant chemotherapy in oropharyngeal carcinoma. French
Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
Br J Cancer 2000 ; 83 : 1594-8.
47. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized
phase III trial of neoadjuvant chemotherapy in head and neck
cancer: 10-year follow-up. J Natl Cancer Inst 2004 ; 96 : 1714-
7.
48. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for
advanced resectable oropharyngeal carcinoma: a University of
Pennsylvania Phase II Trial. J Clin Oncol 2002 ; 20 : 3964-71.
49. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and
paclitaxel followed by concomitant paclitaxel, fluorouracil, and
hydroxyurea chemoradiotherapy: curative and organ-preserving
therapy for advanced head and neck cancer. J Clin Oncol 2003 ;
21 : 320-6.
50. Posner MR, Norris CM, Wirth LJ, Sequential therapy for the
locally advanced larynx and hypopharynx cancer subgroup in
TAX 324: survival, surgery, and organ preservation. Ann Oncol 2009 ; 20 : 921-7.
51. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano
E, Daly-Schveitzer N. Combined postoperative radiotherapy
and weekly cisplatin infusion for locally advanced head and
neck carcinoma: final report of a randomized trial. Int J Radiat
Oncol Biol Phys 1996 ; 36 : 999-1004.
52. Smid L, Budihna M, Zakotnik B, et al. Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2003 ; 56 : 1055-62.
53. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 ; 350 : 1945-
52.
54. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamouscell carcinoma of the head and neck. N Engl J Med 2004; 350 :
1937-44.
55. Winquist E, Oliver T, Gilbert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and
neck: a systematic review with meta-analysis. Head
Neck 2007 ; 29 : 38-46.
56. Schneider MR, Wolf E. The epidermal growth factor receptor
ligands at a glance. J Cell Physiol 2009 ; 218 : 460-6.
57. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus
cetuximab for locoregionally advanced head and neck cancer:
5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010 ; 11 : 21-8.
58. H. J. Wanebo, M. Ghebremichael, B. Burtness, et al. Phase II
evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin,
and radiation for stage III/IV operabıle squamous cancer of the
head and neck (ECOG, E2303). Journal of Clinical Oncology
2007(6015) ; 25 : 18S
59. Kies MS, Harris J, Rotman MZ et al. Phase II randomized trial
of postoperative chemoradiation plus cetuximab for high-risk
squamous cell carcinoma of the head and neck (RTOG 0234).
Int. J. Radiat. Oncol. Biol. Phys. 2009(29) ; 75:, S15.

Thank you for copying data from http://www.arastirmax.com